MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ejh.12891

Медицинская библиотека · European journal of haematology · 2017

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

Lestang Elsa, Peterlin Pierre, Le Bris Yannick, Dubruille Viviane, Delaunay Jacques, Godon Catherine, Theisen Olivier, Blin Nicolas, Mahe Beatrice, Gastinne Thomas, Garnier Alice, Touzeau Cyrille, Voldoire Maud, Bene Marie C, Le Gouill Steven, Milpied Noel, Mohty Mohamad, Moreau Philippe, Guillaume Thierry, Chevallier Patrice

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

The role of allogenic stem cell transplantation (ASCT) is still debated in myelofibrosis (MF).

METHODS

A retrospective analyzed was performed to compare the outcome of 71 patients with intermediate-2 or high-risk Dynamic International Prognosis Scoring System+ (DIPSS+) primary (PMF) or secondary (SMF) myelofibrosis with an indication of ASCT as they ultimately underwent the procedure (n=34) or not (n=37).

RESULTS

Five-year overall survival (OS) was not statistically different between both groups (allograft: 52% vs no allograft: 34%, P=.12). However, progression to myelodysplastic syndrome or acute myeloid leukemia at 5 years was significantly lower in transplanted patients (14% vs 50%, P=.01). In univariate analysis, 5-year OS was significantly higher for transplanted vs non-transplanted patients with unfavorable karyotype (75% vs 0%, P=.001), SMF (71% vs 20%, P=.001) or high DIPSS+ score (46% vs 15%, P=.03). There was also a trend for better 5-year OS in allografted patients with high JAK2V617F burden (>65%) (75% vs 8%, P=.07). Interestingly, the survival of patients who did not proceed to ASCT was dramatically increased by the use of ruxolitinib.

CONCLUSIONS

Not all intermediate-2/high-risk DIPSS+ MF patients benefit from ASCT, especially since the introduction of JAK2 inhibitors.

Для цитирования: Lestang Elsa, Peterlin Pierre, Le Bris Yannick, Dubruille Viviane, Delaunay Jacques, Godon Catherine, Theisen Olivier, Blin Nicolas, Mahe Beatrice, Gastinne Thomas, Garnier Alice, Touzeau Cyrille, Voldoire Maud, Bene Marie C, Le Gouill Steven, Milpied Noel, Mohty Mohamad, Moreau Philippe, Guillaume Thierry, Chevallier Patrice. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?. European journal of haematology. 2017. DOI: 10.1111/ejh.12891.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.